Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The purpose of this study was to conduct a systematic review on the cost-effectiveness of enhanced recovery after surgery (ERAS) protocols in abdominally based autologous breast reconstruction. Further, we reviewed the use of liposomal bupivacaine transversus abdominis plane (TAP) blocks in abdominal autologous reconstruction.
Methods: PubMed, Embase, Cochrane, and Scopus were used for literature review, and PRISMA guidelines were followed. Included articles had full-text available, included cost data, and involved use of TAP block. Reviews, case reports, or comparisons between immediate and delayed breast reconstruction were excluded. Included articles were reviewed for data highlighting treatment cost and associated length of stay (LOS). Cost and LOS were further stratified by treatment group (ERAS versus non-ERAS) and method of postoperative pain control (TAP versus non-TAP). Incremental cost-effectiveness ratio (ICER) was used to compare the impact of the above treatments on cost and LOS.
Results: Of the 381 initial articles, 11 were included. These contained 919 patients, of whom 421 participated in an ERAS pathway. The average ICER for ERAS pathways was $1664.45 per day (range, $952.70-$2860). Average LOS of ERAS pathways was 3.12 days versus 4.57 days for non-ERAS pathways. The average ICER of TAP blocks was $909.19 (range, $89.64-$1728.73) with an average LOS of 3.70 days for TAP blocks versus 4.09 days in controls.
Conclusions: The use of ERAS pathways and postoperative pain control with liposomal bupivacaine TAP block during breast reconstruction is cost-effective. These interventions should be included in comprehensive perioperative plans aimed at positive outcomes with reduced costs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11073775 | PMC |
| http://dx.doi.org/10.1097/GOX.0000000000005793 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Current status of an implant-based augmentation mammaplasty in Korean women: Implications for risk management and social sustainability of breast implant industry in the context of the first Korean case of a medical device fraud.
Medicine (Baltimore)
September 2025
Department of Medical and Pharmaceutical Affairs, Doctor CONSULT, Seoul, Korea.
Stakeholders in the breast implant industry in Korea have recently experienced a crisis from breast implant-associated anaplastic large cell lymphoma and the first Korean case of a medical device fraud. We compared the short-term safety between the microtextured devices that are commercially available after the occurrence of breast implant crisis in Korea. The current study was conducted in a cohort of Korean women who had received an implant-based augmentation mammaplasty for aesthetic purposes between November 14, 2020 and October 13, 2022.
View Article and Find Full Text PDFStrategic Design of Aptamer-Guided Aggregation-Induced Emission Nanoparticles for Targeted Photodynamic Therapy in Breast Cancer.
Adv Sci (Weinh)
September 2025
Department of Chemical and Biological Engineering, Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science & Technology, Hong Kong, 999077,
Breast cancer (BC), characterized by its heterogeneity and diverse subtypes, necessitates personalized treatment strategies. This study presents MF3Ec-TBPP nanoparticles (NPs) as a promising approach, integrating an aggregation-induced emission (AIE)-based photosensitizer, TBPP, with the MF3Ec aptamer to enhance targeted photodynamic therapy (PDT) for Luminal A subtype BC cells. The nanoparticles also feature a 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol) shell and dipalmitoyl phosphatidylcholine (DPPC), which stabilize the structure and inhibit singlet oxygen generation, effectively reducing off-target effects and protecting healthy tissues.
View Article and Find Full Text PDFDeep Inferior Epigastric Perforator In-Basket? Evaluation of Patient Electronic Communication Following Autologous Breast Reconstruction.
Aesthet Surg J
September 2025
Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Background: Patient electronic communication (PEC) via secure messaging is important for patient engagement. While PEC has been studied in primary care, data on surgical specialties, particularly plastic surgery, remain limited.
Objectives: This study assessed the volume and content of post-discharge PECs among patients undergoing post-mastectomy autologous breast reconstruction.
Comparison of Breast Reconstruction Strategies Using Exclusive Lipofilling or Prosthesis After Total Mastectomy for Breast Cancer: Satisfaction and Morbidity After More Than 2 Years.
Aesthet Surg J
September 2025
Department of Gynecological and Breast Surgery and Oncology, Assistance Publique des Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière University Hospital, Paris, France.
Background: Total mastectomy for breast cancer is an impactful procedure, and breast reconstruction plays a crucial role for women diagnosed with the disease.
Objectives: The objective of our study is to compare satisfaction, morbidity, and timelines of two breast reconstruction techniques after breast cancer: breast prosthesis and exclusive lipofilling.
Methods: This is a comparative, retrospective, unicentric study on patients who underwent total mastectomy between May 2014 and May 2020.
Invited Commentary on "Prevalence and characteristics of chronic pain following mastectomy and breast reconstruction: A systematic review and meta-analysis".
J Plast Reconstr Aesthet Surg
September 2025
Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan.